Effects of Pulmonary Surfactant on Lung Inflammation in Rats with Endotoxin Induced Acute Respiratory Distress Syndrome

朱光发,张国清,郭海英,张旻,周新

DOI: https://doi.org/10.3969/j.issn.1671-6205.2002.04.005

2002-01-01

Abstract:Objective To examine effects of a porcine pulmonary surfactant (PS) on lung inflammation in experimental rat model of acute respiratory distress syndrome (ARDS) .Methods Thirty-two healthy male adult Sprague-Dawley rats were surgical operated and mechanically ventilated with 50% oxygen (FiQ2).8 animais received no endotoxin were served as healthy control group (H) .24 animals were adminstered 50 nig/ kg of endotoxin intratrachaeally to induce ARDS. When arterial hlood O2 (PaO2) / FiO2≤300 mm Hg.the animals were randomly allocated to 3 groups ( H = 8 each): ARDS model group (M) not receiving PS, immediate ( i.e.early stage) treatment with PS at a dose of 100 mg/kg (E)administered intratrachaeally, late stage(when PaO2;/FiO2≤200 mm Hg,approximately 2 h later) treatment with PS used as E group(L) ,and were ventilated for another 6 h. Total while blood cells (WBC) were counted and the contents of total proteins(TP) ,TNF-α, IL-1β,microphage inflammatory protein 2 (M1P-2) in BALF and MDA,SOD,GSH levels in the lung homogenates were assayed,respectively . Lung histological changes were examined under a light microscope. Results The M group had increased WBC,TP,TNF-α, IL-1β,MIP-2 in BALF, increased MDA,and decreased SOD and GSH in the lung homogenate (all P0.01) as compared with the H group, whereas TP, IL-1β,MIP-2, MDA and SOD in the L group were modestly but statistically significant improved (P0.05 or P0.01) as compared with the M group,and the E group showed further improvement of all measurements above ( P 0.05 or P0.01) as compared with the M group and the L group. Hislological examination revealed severe acute lung injury in the M group,both L group and E group showed less severe than M group,but it was lighter in the E group than the L group.Conclusion Exogenous PS is more effective in reducing lung inflammation and attenuating lung injury when it is used at the early stage of ARDS.